A randomized, double-blind, placebo-controlled clinical trial to evaluate the effects of Qilin Pill on pregnancy outcomes in patients undergoing in vitro fertilization-embryo transfer

Affiliated Hospital of Shaanxi University of Chinese Medicine0 个研究点开始时间: 待定最近更新: 2023年2月20日

适应症

试验速览

暂无简介。

•1. Patients who are willing to take oral medications of traditional Chinese medicine (TCM) and sign the informed consent form;
•2. In line with both the western diagnostic criteria and indications of IVF-ET set by National Health Commission of the People's Republic of China;
•3. Infertility with liver-stagnation and kidney-deficiency according to TCM syndrome differentiation standard;
•4. Aged 25 to 42;
•5. Basal follicle stimulating hormone (bFSH) <=10 IU/L;
•6. Antral follicle count (AFC) >= 8;
•7. Chinese citizens;
•8. Assisted reproduction with IVF-ET (long protocol or ultra-long protocol).

•1. Adenomyosis or uterine fibroids compressing the uterine cavity line;
•2. Untreated hydrosalpinx;
•3. Endometrial diseases being not cured;
•4. Frozen embryo transplantation;
•5. Treatment of TCM for infertility within 3 months;
•6. Patients who are participating or have participated in other clinical trials of TCM within one month;
•7. Contraindications to assisted reproductive technology;
•8. Severe anatomical abnormalities of the reproductive tract;
•9. Repeated implantation failure (RIF, failure to clinical pregnancy after transfer in three or more IVF treatment cycles, with cumulative transfer of at least four cleavage-stage high-quality embryos or three high-quality blastocysts).

发起方

Affiliated Hospital of Shaanxi University of Chinese Medicine